Nanocaged Metal Tags in Massively Multiplexed Leukemia Bioassay and Beyond

大规模多重白血病生物测定及其他领域中的纳米笼金属标签

基本信息

  • 批准号:
    8035589
  • 负责人:
  • 金额:
    $ 17.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-08-01 至 2014-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Characterization of an acute leukemia (AML) cell requires measurement of biomarkers such as proteins, genes and small molecules. An unambiguous biomarker signature cannot be obtained by determining only a few proteins. A quantitative, massively multiplexed bioassay (MMB) for a constellation of proteins, small molecules, and gene transcripts would be a significant medical breakthrough. "Personalized health care", unambiguous disease identification, and patient- specific diagnosis/prognosis will be enabled by the simultaneous quantitative determination of many biomarkers in a patient's sample. We will develop a new, robust, multimetallic tagging system based on functionalized polymer microbeads (PMBs) analyzed by the proven, high-sensitivity, time-resolved, and element-specific detection technique of flow-cytometry inductively- coupled-plasma mass spectrometry (FC-ICP-MS). Our interdisciplinary group of recognized experts will address this significant challenge. Prof. S. Stevenson (Univ. of Southern Mississippi, USM) will optimize the synthesis of 7 different M3N@C80 endometallofullerenes (EMFs) with interference-free metals that are not endogenous in biomedical samples. Prof. S. H. Strauss and Dr. O. V. Boltalina (Colorado State Univ., CSU) will optimize the synthesis of chemical derivatives of the EMFs, determine the optimum type and number of functional groups to achieve uniformity. Preferred derivatives will be sent to Prof. J. P. Phillips (USM), who will attach polymerizable groups to EMF derivatives, optimize preparation of narrow-size-distribution PMBs containing many specific mixtures of the seven metals (all of which will be permanently sequestered in their carbon nanocages and therefore cannot leach out over time). The Univ. of Toronto (UofT) group, led by Prof. V. I. Baranov, will develop purpose-specific analytical methods that combine robotic sample introduction and FC-ICP-MS instrumentation to allow massively multiplexed detection and classification of thousands of multimetallic encoded beads with element-tagged reporter affinity molecules. They will estimate the tagging multiplexity and show the integrity and virtually infinite shelf-life of the tagged PMBs, and that massive multiplexing with thousands of differently tagged PMBs is possible when this technology is reduced to practice. Dr. O. I. Ornatsky (UofT) will perform analyte selection, testing and validation of the encoded beads, immunoassays, and oligonucleotide hybridization, and will covalently link a range of antibodies (Abs) to the surfaces of the tagged PMBs, which will be tested in sandwich assays with secondary Abs linked to a reporter tag. We will prove that our tagging system has the potential to be used for massively multiplexed bioassays in which thousands of antigens, gene transcripts, and small-molecule cell markers for many diseases and conditions are determined simultaneously in a single sample. We will test our massively multiplexed bioanalytical platform on acute myeloid leukemia (AML) cells. We will show the advantages of FC-ICP-MS analysis of multi-metal-tagged PMBs coated with capture Abs against cytokines, chemokines, growth factors, and soluble receptors present in human serum. PUBLIC HEALTH RELEVANCE: The goals of the proposed investigation are the development of an advanced metal encoding system for bead-based assays. This novel system uses combinations of trimetallic endometallofullerenes embedded in polymeric microbeads to encode hundreds of thousands of unique carriers which together with time-resolved multi- element detection by flow-cytometry inductively-coupled-plasma mass spectrometry (FC-ICP-MS) will enable quantitative gene expression analysis and massively multiplexed immunoassays. Unambiguous disease identification and patient-specific diagnosis and prognosis will all be enabled by the simultaneous, rapid, and quantitative determination of many biomarkers in a patient's sample.
描述(由申请人提供):急性白血病(AML)细胞的表征需要测量生物标志物,如蛋白质、基因和小分子。明确的生物标志物特征不能通过仅测定几种蛋白质来获得。一个定量的,大规模多路生物测定(MMB)的蛋白质,小分子和基因转录的星座将是一个重大的医学突破。通过同时定量测定患者样本中的许多生物标志物,将实现“个性化医疗保健”、明确的疾病识别和患者特定的诊断/预后。我们将开发一种基于功能化聚合物微珠(PMB)的新型、稳健的多金属标记系统,该系统通过流式细胞仪电感耦合等离子体质谱(FC-ICP-MS)的成熟、高灵敏度、时间分辨和元素特异性检测技术进行分析。我们的跨学科专家小组将应对这一重大挑战。S.史蒂文森(南密西西比大学,USM)将优化7种不同的M3N@C80内突富勒烯(EMF)的合成,其中无干扰金属在生物医学样品中不是内源性的。S. H.施特劳斯和O. V. Boltalina(科罗拉多州立大学,CSU)将优化EMF化学衍生物的合成,确定最佳官能团类型和数量以实现均匀性。优选的衍生物将被送到J. P.菲利普斯教授(USM),他将把可聚合基团连接到EMF衍生物上,优化含有七种金属的许多特定混合物的窄尺寸分布PMB的制备(所有这些金属都将永久地隔离在碳纳米笼中,因此不会随着时间的推移而浸出)。多伦多大学(UofT)的研究小组,由V.I. Baranov将开发特定目的的分析方法,该方法将联合收割机机器人样品引入和FC-ICP-MS仪器相结合,以允许对数千个具有元素标记的报告亲和分子的多金属编码珠进行大规模多重检测和分类。他们将估计标记的复用性,并显示标记的PMB的完整性和几乎无限的保质期,以及当该技术减少到实践中时,数千个不同标记的PMB的大规模复用是可能的。欧博士I. Ornatsky(UofT)将进行分析物选择、编码珠的检测和验证、免疫测定和寡核苷酸杂交,并将一系列抗体(Ab)共价连接到标记的PMB表面,将在夹心试验中使用连接到报告标签的二级Ab进行检测。我们将证明我们的标记系统有潜力用于大规模多路生物测定,其中在单个样品中同时测定许多疾病和病症的数千种抗原,基因转录物和小分子细胞标记物。我们将在急性髓性白血病(AML)细胞上测试我们的大规模多重生物分析平台。我们将展示FC-ICP-MS分析包被有针对人血清中存在的细胞因子、趋化因子、生长因子和可溶性受体的捕获Ab的多金属标记的PMB的优势。 公共卫生相关性:拟定研究的目标是开发用于微珠检测的先进金属编码系统。该新系统使用嵌入聚合物微珠中的三金属内金属富勒烯的组合来编码数十万个独特的载体,其与通过流式细胞术电感耦合等离子体质谱(FC-ICP-MS)进行的时间分辨多元素检测一起将使得能够进行定量基因表达分析和大规模多重免疫测定。通过同时、快速和定量测定患者样品中的许多生物标志物,将能够进行非抗生素疾病鉴定和患者特异性诊断和预后。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Janice Paige Buchanan其他文献

Janice Paige Buchanan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Janice Paige Buchanan', 18)}}的其他基金

Nanocaged Metal Tags in Massively Multiplexed Leukemia Bioassay and Beyond
大规模多重白血病生物测定及其他领域中的纳米笼金属标签
  • 批准号:
    8504748
  • 财政年份:
    2011
  • 资助金额:
    $ 17.5万
  • 项目类别:
Nanocaged Metal Tags in Massively Multiplexed Leukemia Bioassay and Beyond
大规模多重白血病生物测定及其他领域中的纳米笼金属标签
  • 批准号:
    8308448
  • 财政年份:
    2011
  • 资助金额:
    $ 17.5万
  • 项目类别:
Medical Adhesive for Trauma-Free Bandage Removal
用于无创伤去除绷带的医用粘合剂
  • 批准号:
    7127852
  • 财政年份:
    2007
  • 资助金额:
    $ 17.5万
  • 项目类别:

相似海外基金

Targeting Menin in Acute Leukemia with Upregulated HOX Genes
通过上调 HOX 基因靶向急性白血病中的 Menin
  • 批准号:
    10655162
  • 财政年份:
    2023
  • 资助金额:
    $ 17.5万
  • 项目类别:
Rapid Acute Leukemia Genomic Profiling with CRISPR enrichment and Real-time long-read sequencing
利用 CRISPR 富集和实时长读长测序进行快速急性白血病基因组分析
  • 批准号:
    10651543
  • 财政年份:
    2023
  • 资助金额:
    $ 17.5万
  • 项目类别:
Experimental and preclinical modeling of NUP98-rearranged acute leukemia
NUP98重排急性白血病的实验和临床前模型
  • 批准号:
    10829603
  • 财政年份:
    2023
  • 资助金额:
    $ 17.5万
  • 项目类别:
Rapid Acute Leukemia Genomic Profiling with CRISPR enrichment and Real-time long-read sequencing
利用 CRISPR 富集和实时长读长测序进行快速急性白血病基因组分析
  • 批准号:
    10839678
  • 财政年份:
    2023
  • 资助金额:
    $ 17.5万
  • 项目类别:
A Systems Epidemiology Approach for Predicting Methotrexate Neurotoxicity in Pediatric Acute Leukemia
预测儿童急性白血病甲氨蝶呤神经毒性的系统流行病学方法
  • 批准号:
    10655716
  • 财政年份:
    2023
  • 资助金额:
    $ 17.5万
  • 项目类别:
Anti-CD25 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Leukemia
抗CD25放射免疫治疗和全骨髓照射治疗复发难治性急性白血病
  • 批准号:
    10435886
  • 财政年份:
    2022
  • 资助金额:
    $ 17.5万
  • 项目类别:
mRNA stability and its impact on hematopoiesis and acute leukemia
mRNA稳定性及其对造血和急性白血病的影响
  • 批准号:
    10339742
  • 财政年份:
    2022
  • 资助金额:
    $ 17.5万
  • 项目类别:
Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel Intervention
通过多层次干预使急性白血病临床试验招募多样化
  • 批准号:
    10505579
  • 财政年份:
    2022
  • 资助金额:
    $ 17.5万
  • 项目类别:
Clonal dynamics and chemoresistance mechanisms of minimal residual disease in acute leukemia
急性白血病微小残留病的克隆动力学和化疗耐药机制
  • 批准号:
    10351765
  • 财政年份:
    2022
  • 资助金额:
    $ 17.5万
  • 项目类别:
Anti-CD25 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Leukemia
抗CD25放射免疫治疗和全骨髓照射治疗复发难治性急性白血病
  • 批准号:
    10576955
  • 财政年份:
    2022
  • 资助金额:
    $ 17.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了